These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 2632643)

  • 1. Lymphatic system and microcirculation. Proceedings of the Third International Symposium on Daflon 500 held during the First Mediterranean Congress of Angiology. Corfu, Greece, May 31, 1988.
    Int Angiol; 1989; 8(4 Suppl):1-75. PubMed ID: 2632643
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of Daflon 500 mg on bovine vessels contractility.
    Gargouil YM; Perdrix L; Chapelain B; Gaborieau R
    Int Angiol; 1989; 8(4 Suppl):19-22. PubMed ID: 2632645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different flavonoids present in the micronized purified flavonoid fraction (Daflon 500 mg) contribute to its anti-hyperpermeability effect in the hamster cheek pouch microcirculation.
    Paysant J; Sansilvestri-Morel P; Bouskela E; Verbeuren TJ
    Int Angiol; 2008 Feb; 27(1):81-5. PubMed ID: 18277344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A lymphatic function of Daflon 500 mg.
    Labrid C
    Int Angiol; 1995 Sep; 14(3 Suppl 1):36-8. PubMed ID: 8919263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphagogue and pulsatile activities of Daflon 500 mg on canine thoracic lymph duct.
    Cotonat A; Cotonat J
    Int Angiol; 1989; 8(4 Suppl):15-8. PubMed ID: 2632644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proceedings of a symposium on Fluxum (low molecular weight heparin): a new prophylactic and therapeutic approach to thromboembolic diseases. Held during the 1st Mediterranean Congress of Angiology. Corfu, Greece, June 2, 1988.
    Int Angiol; 1988; 7(3 Suppl):1-47. PubMed ID: 2850321
    [No Abstract]   [Full Text] [Related]  

  • 7. Capillary filtration and lymphatic resorption in diabetes. Application to the pharmacodynamic activity of Daflon 500 mg.
    Behar A; Valensi P; de Champvallins M; Cohen-Boulakia F; Albagli B
    Int Angiol; 1989; 8(4 Suppl):27-9. PubMed ID: 2632646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic properties of Daflon 500 mg.
    Labrid C
    Angiology; 1994 Jun; 45(6 Pt 2):524-30. PubMed ID: 8203782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Venous effect of Daflon. Clinical and pharmacological study using xenon-133-clearance].
    Klemm J
    MMW Munch Med Wochenschr; 1979 Jun; 121(26):891-2. PubMed ID: 112438
    [No Abstract]   [Full Text] [Related]  

  • 10. Vital capillaroscopy on microcirculation: pharmacodynamic activity of Daflon 500 mg in venous insufficiency.
    Balas P; Pagratis N
    Int Angiol; 1989; 8(4 Suppl):51-2. PubMed ID: 2632650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Bioflavonoids and their significance in angiology: focus on diosmin].
    Bogachev VIu; Golovanova OV; Kuznetsov AN; Shekoian AO
    Angiol Sosud Khir; 2013; 19(1):73-81. PubMed ID: 23531663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mechanisms of antioedemic effect of bioflavonoids in experiment].
    Shishlo VK; Malinin AA; Diufzhanov AA
    Angiol Sosud Khir; 2013; 19(2):25-30, 32-3. PubMed ID: 23863788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mediators involved in inflammation: effects of Daflon 500 mg on their release.
    Jean T; Bodinier MC
    Angiology; 1994 Jun; 45(6 Pt 2):554-9. PubMed ID: 8203787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacological, pharmacodynamic and clinical properties of a new vasoactive agent: A meeting on Dalfon 500 mg. Held during the IVth European-American Symposium on Venous Diseases. Washington, D.C., March 31-April 2, 1987.
    Int Angiol; 1988; 7(2 Suppl):1-43. PubMed ID: 3183450
    [No Abstract]   [Full Text] [Related]  

  • 15. Microvascular motricity and haemorheology effects of buflomedil. Symposium held during the International Congress on Angiology. Rome, September 21, 1989. Proceedings.
    Blood Vessels; 1991; 28 Suppl 1():1-44. PubMed ID: 1932762
    [No Abstract]   [Full Text] [Related]  

  • 16. Activity of Daflon 500 mg on the hemorheological disorders in diabetes.
    Lacombe C; Lelievre JC; Bucherer C; Grimaldi A
    Int Angiol; 1989; 8(4 Suppl):45-8. PubMed ID: 2632648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Techniques used to evaluate the cutaneous microcirculation: application of photoplethysmography to the assessment of a phlebotropic agent in the treatment of leg ulcers.
    Guillot B
    Angiology; 1994 Jun; 45(6 Pt 2):542-8. PubMed ID: 8203785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of diosmin upon red blood cell deformability and osmotic fragility. Relationship with lipid content.
    Garnier M; Perret G; Pilardeau P; Vaysse J; Rolland Y; Uzzan B; Vassy R
    Methods Find Exp Clin Pharmacol; 1988 Apr; 10(4):259-62. PubMed ID: 3386333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Modification of lysosomal enzymes using semisynthetic diosmin. Comparative clinical study].
    Marescaux J; Maamer M; Trenque T; Evrard S; Mutter D; Furderer C
    Phlebologie; 1987; 40(4):1043-55. PubMed ID: 3447185
    [No Abstract]   [Full Text] [Related]  

  • 20. Advantage of a micronized flavonoidic fraction (Daflon 500 mg) in comparison with a nonmicronized diosmin.
    Amato C
    Angiology; 1994 Jun; 45(6 Pt 2):531-6. PubMed ID: 8203783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.